carbenicillin indanyl sodium
For Oral Use
Geocillin, a semisynthetic penicillin, is the sodium salt of the indanyl ester of Geopen® (carbenicillin disodium).
Geocillin (carbenicillin indanyl sodium) is indicated in the treatment of acute and chronic infections of the upper and lower urinary tract and in asymptomatic bacteriuria due to susceptible strains of the following organisms:
Morganella morganii (formerly Proteus morganii)
Providencia rettgeri (formerly Proteus rettgeri)
Geocillin is also indicated in the treatment of prostatitis due to susceptible strains of the following organisms:
Enterococcus (S. faecalis)
WHEN HIGH AND RAPID BLOOD AND URINE LEVELS OF ANTIBIOTIC ARE INDICATED, THERAPY WITH GEOPEN (CARBENICILLIN DISODIUM) SHOULD BE INITIATED BY PARENTERAL ADMINISTRATION FOLLOWED, AT THE PHYSICIAN'S DISCRETION, BY ORAL THERAPY.
NOTE: Susceptibility testing should be performed prior to and during the course of therapy to detect the possible emergence of resistant organisms which may develop.
To reduce the development of drug-resistant bacteria and maintain effectiveness of Geocillin and other antibacterial drugs, Geocillin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Published Studies Related to Geocillin (Carbenicillin)
Randomized trial comparing oral ciprofloxacin plus penicillin V with amikacin plus carbenicillin or ceftazidime for empirical treatment of febrile neutropenic cancer patients. [1995.10]
Aminoglycoside-containing combination therapy has been the standard empirical approach for febrile neutropenic cancer patients. With the advent of the broad-spectrum oral fluoroquinolones, it is now possible to evaluate an initial empirical alternative therapy... Oral therapy with ciprofloxacin and penicillin V is a safe alternative to standard parenteral therapy in this low-risk group of neutropenic patients, with unquestionable cost containment.
Ceftazidime with or without vancomycin vs. cephalothin, carbenicillin and gentamicin as the initial therapy of the febrile neutropenic pediatric cancer patient. [1988.03]
In a 28-month randomized trial we compared ceftazidime (CAZ), an extended spectrum cephalosporin, with cephalothin, carbenicillin and gentamicin (KCG) as empiric therapy for febrile neutropenic pediatric cancer patients. Because of the occurrence of ceftazidime-resistant Gram-positive primary infections, vancomycin was added to CAZ after the first year of study...
Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa. [1987.07]
A randomized cross-over study was undertaken to compare nebulized (1) ceftazidime with (2) a combination of gentamicin and carbenicillin, and (3) saline, each given for 4 months, in patients with cystic fibrosis infected with Pseudomonas aeruginosa. Mean peak expiratory flow on ceftazidime, 299 litres/min, and on gentamicin and carbenicillin, 297 litres/min, were greater than on saline, 278 litres/min (P less than 0.02 and P less than 0.05 respectively)...
Development and validation of an LC method for the quantitation of carbenicillin in human serum. [1994.06]
An LC method for the quantitation of carbenicillin in human serum has been developed and validated. After protein precipitation with acetonitrile and evaporation, the residue was taken up by citric acid at pH 1.9... Stabilities of on-system, bench top, freeze-thaw cycles and sample storage were established.
Adverse reactions to prolonged treatment with high doses of carbenicillin and ureidopenicillins. [1991.01]
Charts were reviewed for 63 patients whose chronic pseudomonas osteomyelitis was treated with high doses of extended-spectrum penicillins for prolonged periods. The incidence of untoward drug reactions was significantly higher than expected...
Clinical Trials Related to Geocillin (Carbenicillin)
Zithromax EV in Community-Acquired Pneumonia (CAP) [Completed]
The intravenous (IV) regimen containing azithromycin (Zithromax) plus ampicillin-sulbactam is
consistent with current guidelines for the treatment of CAP. In fact the International
guidelines for the treatment of CAP in hospitalised patients suggests the use of a
combination between a b-lactam and a macrolide.
This trial will allow investigators to evaluate the efficacy of azithromycin plus
ampicillin-sulbactam in the treatment of hospitalized subjects with community acquired
pneumonia. In addition, this trial will allow investigators to evaluate the safety and
toleration of combination therapy.
Study Comparing the Safety and Efficacy of Tigecycline With Ampicillin-Sulbactam or Amoxicillin-Clavulanate to Treat Skin Infections [Recruiting]
The purpose of this study is to compare the safety and efficacy of the antibiotic tigecycline
with other antibiotics, ampicillin-sulbactam, and amoxicillin-clavutanate in the treatment of
a complicated skin and/or skin structure infection (cSSSI).
Prospective Comparison of Ampicillin / Amoxicillin Versus Ceftriaxone for the Treatment of Salmonella Infections in AIDS Patients [Completed]
To compare the effectiveness of standard treatment with parenteral ampicillin and oral
amoxicillin compared to initial daily therapy with ceftriaxone followed by 3 times weekly
suppressive treatment for salmonella infections in AIDS patients.
The Efficacy of Prophylactic Antibiotic Administration During Breast Cancer Surgery in Overweight Patients. [Recruiting]
This is a single center trial to compare the rate of surgical site infection in normal (BMI
equal to or less than 25) and overweight (BMI over 25) women who are undergoing breast
cancer surgery. The overweight patients are further randomized into two groups; in one group
patients receive prophylactic antibiotics (ampicillin/sulbactam), in the other they do not.
Management of Early Onset Neonatal Septicaemia: Selection of Optimal Antibacterial Regimen for Empiric Treatment [Completed]
A prospective two-center antibiotic regimen switch study will be conducted to compare the
clinical efficacy of two antibiotic regimens - penicillin/gentamicin versus
ampicillin/gentamicin - in the empirical treatment of early onset neonatal sepsis. The
influence of either regimen on bowel colonization pattern and on the development of
antibiotic resistance of gut microflora will also be assessed. The primary endpoint is the
need for a change in antibacterial treatment within 72 hours of therapy, based on pre-defined
criteria. Secondary endpoints will be the incidence rate and etiology of early and late onset
neonatal sepsis and susceptibility pattern of causative microorganisms; mortality rate within
60 days; duration of hospitalization in NICU; duration of artificial ventilation;
colonization pattern and susceptibility of colonizing bacteria (including resistance to
empiric antibiotic regimen).